A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides

Purpose

The researchers are doing this study to test the safety of combining bexarotene with TSEB radiotherapy in people who have a common form of CTCL called mycosis fungoides (MF). Bexarotene is a form of vitamin A that activates proteins called retinoid X receptors, which may stop the growth of cancer cells and kill them. TSEB radiotherapy is a type of radiation therapy that treats the entire surface of the skin with very low doses of radiation to kill cancer cells and shrink tumors. This type of radiation does not pass through the outer layers of the skin into the tissues and organs below the skin. The study researchers think that giving bexarotene treatment at the same time as treatment with TSEB radiotherapy may be more effective against MF than either treatment given alone or in sequence (one after the other).

Condition

  • Cutaneous T-cell Lymphoma

Eligibility

Eligible Ages
Over 18 Years
Eligible Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Age ≥18 years - Pathologically confirmed cutaneous T-cell lymphoma consistent with mycosis fungoides (MF) based on biopsy done or reviewed at MSKCC - Stage IB or higher MF per ISCL/EORTC criteria; concurrent diagnosis of Sézary syndrome permissible. Patients who have not had prior systemic therapies and refractory/relapsed patients are eligible. - Baseline mSWAT score of at least 10 - Stable topical steroids or systemic antipruritic agent (e.g. antihistamines, doxepin, GABA analogs) preceding study entry is permissible, but no new prescribed or over the counter topical or systemic anti-pruritics started post-enrollment - Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 - Ability to provide informed consent

Exclusion Criteria

  • Any oral retinoid therapy for any indication within 3 weeks of the first dose of study drug - Prior TSEB (prior focal skin-directed RT acceptable) - Concurrent diagnosis of systemic anaplastic large cell lymphoma (ALCL) or another non-Hodgkin lymphoma - Concurrent diagnosis of additional non-skin malignancy - Pregnancy - Patients unwilling to use two forms of barrier contraception while taking study medication - Receipt of treatment with another investigational device or drug (at present or within 2 weeks of enrollment) - Familial hypertriglyceridemia or other medical conditions in which use of bexarotene would be contraindicated - High likelihood of protocol non-compliance (in opinion of investigator) - Systemic steroids within two weeks of first dose of study drug (patients on systemic steroids for non-disease related conditions will be permitted per investigator discretion) Prohibited concurrent medications - Gemfibrozil is contraindicated as may increase bexarotene concentrations - Bexarotene is a minor CYP3A4 substrate: avoid strong/moderate CYP3A4 inducers and inhibitors, if possible, but concomitant use is not a contraindication Bexarotene is a moderate CYP3A4 inducer: avoid concurrent administration with CYP3A4 sensitive substrates, for which minimal concentration changes may lead to therapeutic failures of the substrate (e.g. cyclosporine, tacrolimus, sirolimus, quinidine, fentanyl), if possible

Study Design

Phase
Phase 1
Study Type
Interventional
Allocation
N/A
Intervention Model
Single Group Assignment
Intervention Model Description
This is a Phase I, single-arm therapeutic study for patients with diffuse cutaneous T-cell lymphomas (CTCL).
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Bexarotene Combined With Radiotherapy 		Patients will be initiated on bexarotene 150 mg daily on Day 1, with dose increase to 300 mg daily on Day 15. Patients will receive Cycle 1 of TSEB on Day 22 (with 2 Gy given on two consecutive days -Day 22 and 23), with safety assessment on Day 52. Efficacy will first be assessed on Day 52 and then again on Day 82 by global response assessment, including mSWAT. Patients who have less than 70% reduction from baseline mSWAT score will be eligible for subsequent cycles of TSEB (administered as 4 Gy over 2 consecutive days), until mSWAT score reduction of ≥ 70%, and up to a total of 6 cycles. Treatment may continue until disease progression, unacceptable toxicity, recommended termination by treating physician, or termination of the study.
  • Drug: Bexarotene
    Orally every day starting at the dose of 150 mg/day flat dose. At Day 15, if the treatment is tolerated, patients will escalate the dose of bexarotene to 300 mg/day, and that dose will remain constant during the rest of the study.
    Other names:
    • Targretin®
  • Radiation: Total Skin Electron Beam (TSEB)
    At Day 21, if the bexarotene has shown to be tolerated, patients will receive the first dose of TSEB (2 Gy x 2).

Recruiting Locations

Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities)
Commack 5113412, New York 5128638 11725
Contact:
Brandon Imber, MD
631-212-6346

Memorial Sloan Kettering Cancer Center (All Protocol Activities)
New York 5128581, New York 5128638 10065
Contact:
Brandon Imber, MD
631-212-6346

Memorial Sloan Kettering Nassau (Limited Protocol Activites)
Rockville Centre 5134203, New York 5128638 11553
Contact:
Brandon Imber, MD
631-212-6346

More Details

NCT ID
NCT05296304
Status
Recruiting
Sponsor
Memorial Sloan Kettering Cancer Center

Study Contact

Brandon Imber, MD, MS
631-212-6346
imberb@mskcc.org

For help using this page: trialstoday@researchmatch.org or call 855-514-7001

ResearchMatch is funded in part by the National Institutes of Health (NIH) Clinical and Translational Science Award (CTSA) program, led by the NIH’s National Center for Advancing Translational Sciences (NCATS), grants UL1TR000445 and 1U54RR032646-01, and grant U24TR001579 from NCATS and the National Library of Medicine. The content of this website is solely the responsibility of ResearchMatch and Vanderbilt University and does not necessarily represent the official views of the NIH, NCATS, or NLM.

Vanderbilt University Medical Center